Psychometric properties of a generic, patient-centred palliative care outcome measure of symptom burden for people with progressive long term neurological conditions by Gao, Wei et al.
Gao, Wei and Crosby, Vincent and Wilcock, Andrew and 
Burman, Rachael and Silber, Eli and Hepgul, Nilay and 
Chaudhuri, K. Ray and Higginson, Irene J. (2016) 
Psychometric properties of a generic, patient-centred 
palliative care outcome measure of symptom burden for 
people with progressive long term neurological 
conditions. PLOS ONE, 11 (10). e0165379. ISSN 1932-
6203 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/48269/1/Wilcock%20A%20Palliative%20Care%20Outcome
%20measure%20in%20neurologu%20Plos%20One.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
RESEARCH ARTICLE
Psychometric Properties of a Generic,
Patient-Centred Palliative Care Outcome
Measure of Symptom Burden for People with
Progressive Long Term Neurological
Conditions
Wei Gao1*, Vincent Crosby2, Andrew Wilcock3, Rachael Burman1, Eli Silber4,
Nilay Hepgul1, K Ray Chaudhuri5, Irene J. Higginson1, on behalf of the OPTCARE Neuro
trial¶
1 King’s College London, Faculty of Life Sciences and Medicine, Department of Palliative Care, Policy and
Rehabilitation, Cicely Saunders Institute, London, United Kingdom, 2 Palliative Medicine, Nottingham
University Hospitals NHS Trust, Nottingham, United Kingdom, 3 Palliative Medicine and Medical Oncology,
School of Medicine, University of Nottingham, Nottingham, United Kingdom, 4 Department of Neurology,
Kings’ College Hospital, London, United Kingdom, 5 National Parkinson Foundation Centre of Excellence,
Kings College Hospital and Kings College, London, United Kingdom
¶ Membership of the OPTCARE Neuro trial is provided in the Acknowledgments.
* wei.gao@kcl.ac.uk
Abstract
Background
There is no standard palliative care outcome measure for people with progressive long
term neurological conditions (LTNC). This study aims to determine the psychometric prop-
erties of a new 8-item palliative care outcome scale of symptom burden (IPOS Neuro-S8) in
this population.
Data and Methods
Data were merged from a Phase II palliative care intervention study in multiple sclerosis
(MS) and a longitudinal observational study in idiopathic Parkinson’s disease (IPD), multi-
ple system atrophy (MSA) and progressive supranuclear palsy (PSP). The IPOS Neuro-S8
was assessed for its data quality, score distribution, ceiling and floor effects, reliability, fac-
tor structure, convergent and discriminant validity, concurrent validity with generic (Pallia-
tive care Outcome Scale) and condition specific measures (Multiple Sclerosis Impact
Scale; Non-motor Symptoms Questionnaire; Parkinson’s Disease Questionnaire), respon-
siveness and minimally clinically important difference.
Results
Of the 134 participants, MS patients had a mean Extended Disability Status Scale score
7.8 (SD = 1.0), patients with an IPD, MSA or PSP were in Hoehn & Yahr stage 3–5. The
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IPOS Neuro-S8 had high data quality (2% missing), mean score 8 (SD = 5; range 0–32), no
ceiling effects, borderline floor effects, good internal consistency (Cronbach’s α = 0.7) and
moderate test-retest reliability (intraclass coefficient = 0.6). The results supported a moder-
ately correlated two-factor structure (Pearson’s r = 0.5). It was moderately correlated with
generic and condition specific measures (Pearson’s r: 0.5–0.6). There was some evidence
for discriminant validity in IPD, MSA and PSP (p = 0.020), and for good responsiveness
and longitudinal construct validity.
Conclusions
IPOS Neuro-S8 shows acceptable to promising psychometric properties in common forms
of progressive LTNCs. Future work needs to confirm these findings with larger samples
and its usefulness in wider disease groups.
Introduction
Progressive long term neurological conditions (LTNC) are a group of irreversible and degener-
ative diseases of the nervous system that share some common characteristics, such as an
increasing deterioration in neurological function over time, leading to increasing disability,
cognitive impairment and dependence on others. As the disease progresses, complex physical,
psychosocial and spiritual issues can arise which require palliative care and integrated care pro-
visions frommultiple agencies [1–3]; the primary care focus also moves from cure to comfort,
and the patient perspectives become central [4]. Little research is conducted on how best to
integrate and coordinate these care services, and on the effectiveness of different care models
among this population. One major barriermay be the lack of appropriate patient centred palli-
ative care outcome measures (PCOM).
A number of disease specific PCOMs are in existence for LTNCs, e.g. the Multiple Sclerosis
Impact Scale (MSIS-29)[5], the Parkinson’s DiseaseQuestionnaire (PDQ-39, PDQ-8) [6, 7],
and Non-Motor Symptoms Questionnaire (NMSQuest) [8], but all of these measures fail to
adequately address the progressive nature of the LTNC and the resulting complex needs
including palliative care needs. For example, none of the existing measures feature pain, dys-
pnoea and other distressing symptoms which are frequently reported by patients and are rec-
ommended as triggers for palliative care referral [1, 2, 9, 10].
The 10-item palliative care outcome scale (core POS) is a widely used PCOM for palliative
care patients. However, it was designed for general palliative care purposes and when applied to
LTNCs it is not as sensitive as themeasure primarily focusses on key symptoms that require palli-
ative care input [10–12]. A brief PCOM for palliative care needs, comprising five typical symp-
toms (pain, nausea, vomiting, mouth problems and sleeping difficulty),was found to have
satisfactory psychometric properties and was sensitive to change in patients with multiple sclero-
sis (MS) [11–13]. In an observational study in patients with idiopathic Parkinson’s disease (IPD),
multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), a 20-itemmeasure
coveringmore comprehensive aspects of palliative care needs including symptoms was used [14].
It appears to be a promising tool but has not yet been through formal psychometric evaluation.
Based on the well validated core POS [15–17], several commonly used condition specific POS
symptom versions [10–12], and clinical management guidelines for LTNCs [18, 19], we devel-
oped a new patient reported, integrated palliative care outcomemeasure that may be used to eval-
uate the outcome for people with progressive LTNC (IPOSNeuro).
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A key component in the IPOS Neuro is the symptom burden, a concept that encompasses
both the severity of the symptoms and the patient's perception of the impact of the symptoms
[20]. This study provides a formal evaluation of the psychometric properties of the symptom
burden specifically associated with eight core symptoms in the IPOS Neuro. For the conve-
nience of reference, we named this subscale version the IPOS Neuro-S8. We examined five psy-
chometric aspects: data quality, floor and ceiling effects, internal consistency and test-retest
reliability, cross-sectional construct validity. We also provided a preliminary validation on
responsiveness and longitudinal validity, and an initial estimate of the minimally clinically
important difference (MCID).
Data and Methods
Ethical Approval
The Ethical approval for the MS trial was granted by the King’s CollegeHospital NHS Trust
Local Research Ethics Committee (protocol number: 01-04-018); the IPD,MSA & PSP study
was approved by both the Research Ethics Committee of the Institute of Psychiatry and King’s
CollegeHospital NHS Foundation Trust (REC number: 05/Q0703/196).Written consent was
given by all participants in both studies, through consent forms approved by the Research Eth-
ics Committees.
Setting and Design
Data was pooled from two studies: A) a randomised Phase II trial evaluating effectiveness of a
short-term palliative care intervention in people severely affected by multiple sclerosis (MS)
[11]; B) a longitudinal community based study in IPD, MSA and PSP [14]. Both studies were
conducted in South East England (including London, Kent and Sussex) with the MS trial pri-
marily focusing on patients living in South East London. Patients were recruited from a neuro-
sciences Centre based at King’s CollegeHospital (KCH). This Centre is the second largest
regional neuroscience centre in the UK and serves an estimated population of 3.5 million
people.
Eligibility Criteria
Patients with MS were included if their usual clinician deemed them to have one or more of
unresolved symptoms, psychosocial concerns, end-of-life issues, progressive illness, or complex
needs(i.e., palliative care needs); patients with a clinical diagnosis of IPD, MSA or PSP, who fell
into Hoehn and Yahr (HY) stages 3–5 for IPD or equivalent motor disability for MSA and PSP
[21].
In both studies, patients with urgent needs for symptom control, or support, or who were
deteriorating rapidly or dying were excluded. Patients living in nursing homes were also
excluded. The MS trial patients were randomly allocated to either the control or the interven-
tion group, and the two groups were comparable for all factors. There was no clinically detect-
able change at 6 weeks on any clinically important variables [11].
Measures
The 8 key symptom subscale of the Integrated Palliative care Outcome Scale for neuro-
logical conditions (IPOSNeuro-S8). A generic, patient-centred palliative outcome measure
of symptom burden for people with progressive LTNCs. It is based on a validated symptom
burden measure in advanced multiple sclerosis—palliative care outcome scale, 5 symptoms
(POS-MS-5)[11]. The POS-MS-5 assesses five key symptoms—pain, nausea, vomiting, mouth
Psychometric Properties of an Outcome Measure for Long Term Neurological Conditions
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problems and sleeping difficultiesover the past three days. To extend its use to the other neuro-
logical conditions, three further symptoms (breathlessness, spasms and constipation) prevalent
in LTNCs are included to form the IPOS Neuro-S8 [18, 19, 22]. Each item is rated on a Likert
scale from 0 (no problem) to 4 (overwhelming problem), with a total score range from 0 to 32
(S1 File). We propose to incorporate it into a 45-item integrated palliative care outcome mea-
sure (IPOS Neuro), with 37 items asking about symptom experience and the remaining items
asking about information needs, practical concerns, anxieties of the patient and family, and
their overall feeling of being at peace (S2 File).
The Core Palliative care Outcome Scale (Core POS). A well validated and commonly
used generic palliative care outcome measure [13, 15, 16]. It comprises of 10 items asking
patients about their physical symptoms, information and practical needs, patient and family
anxiety and well-being. The impact of the items on patients over the past three days is scored
using a five-point Likert scale system, ranging from 0 (no problem) to 4 (overwhelming prob-
lems). The total score range is 0 to 40.
TheMultiple Sclerosis Impact Scale (MSIS-29). A disease-specifichealth related quality
of life measure, with two subscales assessing physical and psychological impact of multiple sclero-
sis (MS)[5, 23]. It has a 20-item physical impact scale and a 9-item psychological impact scale.
Each item on theMSIS has a five-point response option (1–5): “not at all,” “a little,” “moder-
ately,” “quite a bit” and “extremely.” Scores on the physical impact scale can range from 20 to
100 and on the psychological impact scale from 9 to 45, with lower scores indicating little impact
of MS and higher scores indicating greater impact. In this study, we used these two subscales.
The Parkinson’s diseaseQuestionnaire (PDQ-8). An 8-item self-completed, Parkinson’s
disease specific questionnaire. Each item is rated: 0 (never) to 4 (always/cannot do) in the past
one month. Items are: problems getting around in public, difficulty dressing self, felt depressed,
embarrassed in public due to having disease, problems with close personal relationships, prob-
lems with concentration, unable to communicate with people properly, painful muscle cramps
or spasms. The PDQ-8 Summary Index is expressed as a percentage of the sum of the items
scores on the maximum possible scale score [6, 7].
The Non-Motor Symptoms Questionnaire (NMSQuest-30). A 30-item self-adminis-
tered, Parkinson’s disease specific questionnaire with three response categories (“yes”, “no”
and “don’t know”) for each item. The items are divided into six domains: neuropsychiatric
symptoms, autonomic disorders, disorders of smell, sleep disorders, sensory symptoms and
other symptoms [8, 24]. Total NMSQuest scores range from 0 to 30 based on the total number
of “yes” responses. Scores indicate how many different non-motor symptoms are present.
Othermeasures. The ExtendedDisability Status Scale (EDSS) is a single item 10-point cli-
nician rated classification scheme used to assess physical disability for patients with MS [25].
The score range 0 (normal neurological exam) to 10 (death due to MS) with a step increase of
0.5. EDSS 1.0 to 4.5 refer to people with a high degree of ambulatory ability, 5.0 to 9.5 refer to
the loss of ambulatory ability. The modifiedHoehn & Yahr scale (HY) is a measure of the
symptom progression for IPD, MSA and PSP, where stage 3, 4 and 5 respectively indicate
“mild to moderate bilateral disease; some postural instability; physically independent”, “Severe
disability; still able to walk or stand unassisted” and “Wheelchair bound or bedriddenunless
aided” [21]. The EuroQoL 5-Dimensions Questionnaire (EQ-5D) is a widely used generic
instrument of health related quality of life [26]. It includes a descriptive part and a visual ana-
logue scale for current health status (EQ-VAS, score range: 0 = the worst possible health status
to 100 = the best possible health status). The descriptive part consists of five questions asking
respondent’s current health in dimensions, i.e. mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. The rating on these five items is converted to a value (EQ-index)
using the UK weighting schemes [27].
Psychometric Properties of an Outcome Measure for Long Term Neurological Conditions
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Data Collection and Follow Up Schedule
Details of data collection and follow up schedule have been described elsewhere [11, 14, 28]. In
brief, data were collected through face-to-face interviews in both studies. Socio-demographic
information, clinical characteristics and the summary scores of patient reportedmeasures were
recorded at baseline. The patients in both studies were followed up at 12 weeks, and the
patients with MS had a further data collection point at 6 weeks.
Statistical Analysis
Total scores and item specific scores were describedusing mean and standard deviation (SD).
Individual items were examined for their frequency distribution and expressed as a percentage.
Floor and ceiling effects were measured by the number of respondents receiving the low (0–2)
and high range (30–32) summary scores, or the minimum (0) and maximum (4) score on the
individual items, respectively. The floor and ceiling effects were deemed present whenmore
than 15% of patients recorded the extreme scores [29]. Data quality was assessed by the com-
pleteness of responses.
To evaluate the dimensions of the scale, exploratory factor analysis (EFA) and confirmatory
factor analysis (CFA) were used. The EFA was conducted using the maximum likelihood
method with promax rotation. The number of factors were determined by Spree plot and Kai-
ser’s criterion of an Eigen value>1. A factor loading greater than 0.30 was considered signifi-
cant. The factorial structure of the scale was verified by CFA [30]. Several fit indices were
selected to assess the CFA model fit: chi-square test statistics, root-mean-squared error of
approximation (RMSEA), standardised root mean square residual (SRMR), and Comparative
Fit Index (CFI) [31, 32]. RMSEA is a measure of the average of the residual variance and
covariance; goodmodels have RMSEA values that are at or less than 0.08. SRMR is a measure
of the mean absolute value of the covariance residuals; values below 0.05 indicate good fit; CFI
is an index that falls between 0 and 1, with values greater than 0.95 considered being indicators
of good fitting models.
The internal consistency of the scale was calculatedwith Cronbach's alpha coefficient (mini-
mum acceptable value for alpha was 0.7) [33]. Pearson’s correlation coefficient (r, 95%CI) was
used to evaluate the concurrent and the convergent validity. The IPOSNeuro-S8 was anticipated
to bemore strongly correlated with physical domain than non-physical domain, e.g. in MS,
higher inMSIS physical thanMSIS psychological, and in IPD, MSA& PSP higher in NMSQuest
than in PDQ-8. The interpretation of an absolute r value is as follows:0.35—low or weak corre-
lations, 0.36 to 0.67—modest or moderate correlations, and 0.68 to 1.0—strong or high correla-
tions [34]. Discriminant validity was assessed using the known-groups validationmethod.
Patients with higher level of disability were expected a priori to have a higher need for palliative
care compared with patients with lower level of disability (EDSS<8 versus 8+ inMS, HY3 versus
HY4&5 in IPD, MSA& PSP, respectively). The mean difference between groups was compared
with the two sample t-test.
The test-retest reliability was explored with the intraclass correlation coefficient (ICC),
using the baseline and six-week data from the MS trial only. The responsiveness of the IPOS
Neuro-S8 was evaluated using the change scores from baseline to 12 week follow up. Two
aspects were assessed and compared using independent t-test: responsiveness to intervention
(MS trial), and to disease trajectory by diagnosis (IPD versus MSA & PSP). The responsiveness
in MS sample was also analysed with effect size, interpreted using Cohen’s rules [35]. Longitu-
dinal concurrent validity was tested using Pearson’s correlation coefficient r on the change
scores betweenmeasures.
Psychometric Properties of an Outcome Measure for Long Term Neurological Conditions
PLOS ONE | DOI:10.1371/journal.pone.0165379 October 25, 2016 5 / 15
The minimal clinically important difference (MCID) was derived using the distribution
based approach [36]. The MCID was estimated by the standard error of measurement (SEM),
one half and one third of the standard deviation of the change score [37, 38]. Strictly speaking,
SEM is a measure of the precision of the scale. As a precision measure, it has an arbitrary crite-
rion (e.g.<1/2 or 1/3 SD) to be deemed as appropriate [39]. However, 1 SEM can be used as an
approximation to the MID, along with other distribution-basedmethods for interpreting
PROMs that produce dissimilar results [40].
All statistical tests were two-sided, P<0.05 was considered statistically significant. Data
were analysed by SAS 9.4 (SAS Institute Inc, Cary, USA).
Results
Characteristics of the Study Participants
The pooled sample consists of 134 patients (Table 1). The average age of the study participants
was 62 years old (SD = 12). Patients with MS were younger than patients with IPD, MSA or
PSP (53 vs 66 years, p<0.001). Most patients with MS were women (69%), while gender was
more balanced in IPD, MSA and PSP sample (55% vs 45%). 94% of patients with MS were in
primary- or secondary-progressive stage (44% and 50%, mean EDSS score = 7.8(SD = 1.0)).
Patients with MSA and PSP (71% in H&Y stage 4 & 5) were in more advanced disability stages
than those with IPD (60% in H&Y stage 4 & 5). The disease duration was significantly shorter
in MSA and PSP (4 years) than in MS (15.5 years) or IPD (12 years) (p<0.0001).
Scale- and Item-Level Descriptive Statistics and Frequency Distribution
The mean total score of the IPOS Neuro-S8 was 7.8 (SD = 4.8); the score distribution appeared
to be near normal with a kurtosis of -0.008 and a skewness of 0.54 (p value for Shapiro-Wilk
test<0.001) (Table 2). All of the five response categories (0–4) were used in both conditions.
Only a small proportion of patients scored the highest possible score (4) on the individual
Table 1. Demographic and clinical characteristics in MS and IPD, MSA & PSP samples.
Characteristics Value All(n = 134) MS(n = 52) IPD, MSA & PSP
All(n = 82) IPD(n = 50) MSA(n = 17) PSP(N = 15)
Age Mean(SD) 61.6(12) 53.0(10) 66(9) 66.5(8) 67(8) 69(12)
Median(min, max) 64(33,86) 52(33,75) 68(38, 86) 67(40,80) 68(51,81) 71(38,86)
Gender Woman% 73(54%) 36(69%) 37(45%) 23(46%) 6(35%) 8(53%)
Diagnosis Primary: secondary: other - 23:26:3 NA
Disease stage/progressiveness Mean EDSS score(SD) - 7.8(1.0)
Median EDSS (min-max) - 8.0(5.5–9.5)
H&Y 3:4:5 - - 29:37:34% 40:38:22% 12:41:47% 13:27:60%
Duration of illness since diagnosis Mean(SD) 12.4(8.5) 17.2(9.6) 9.3(6.0) 11.9(5.8) 5.9(4.0) 4.6(2.7)
Median(min, max) 12(0,54) 15.5(0,54) 8.0(1, 25) 12(1,25) 5(1,14) 4(1,11)
Employment Retired 72(54%) 11(21%) 61(74%) 38(76%) 11(65%) 12(80%)
In employment/self employed 7(5%) 1(2%) 6(7%) 6(12%) 9(0%) 0(0%)
Unable to work(due to illness) 55(41%) 40(77%) 15(18%) 6(12%) 6(35%) 3(20%)
Ethnic group White% 113(84%) 47(90%) 66(80%) 37(74%) 17(100%) 12(80%)
Living arrangement Lives with carer 104(78%) 41(79%) 63(77%) 36(72%) 14(82%) 13(87%)
Lives alone 23(17%) 9(17%) 14(17%) 10(20%) 2(12%) 2(13%)
Other 7(5%) 2(4%) 5(6%) 4(8%) 1(6%) 0(0%)
Hoehn & Yahr stage refers to: 3 Mild to moderate bilateral disease; some postural instability; physically independent; 4 Severe disability; still able to walk or
stand unassisted; 5 Wheelchair-bound or bedridden unless aided.
doi:10.1371/journal.pone.0165379.t001
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items. Other than nausea and vomiting, all items were roughly symmetrical around the score
range 0–3. The mean total score of the IPOS Neuro-S8 was higher in IPD, MSA & PSP than in
MS (9.0 vs 6.0, p<0.001); the average scores for the pain, shortness of breath, mouth problems
and difficulty in sleep items followed a similar pattern and were significantly different between
MS and IPD, MSA & PSP (p<0.05). No difference was found in spasms, nausea, vomiting and
constipation scores by condition (p>0.09).
Missing Data, Floor and Ceiling Effects
The rate of missing data for the IPOS Neuro-S8 was low, with only 5.8% of total scores missing
in the MS sample and no missing for IPD, MSA & PSP patients (Table 2). The items missing in
the MS data was in a small range (3.8–5.8%). The missing pattern appeared to be scale missing
and was not related to individual items or observed factors. There was evidence for a borderline
floor effect, with 14.9% of the patients scoring 0–2; the floor effect was evident in patients with
MS (28.9%) but not for IPD, MSA & PSP patients (6.1%). There was no ceiling effect for the
total score in the combined data or for both diagnostic groups. The floor effect was present for
all items, with 23 to 91% of the patients receiving the lowest possible score (0).
Factor Structure
The EFA indicated a two-factor structure (P = 0.67, X2 = 10.2, df = 13), with factor 1 loaded
with five items and factor two with three items (Table 3). All fit indices in the CFA met accept-
able level model fit. The two factors were moderately correlated (Pearson’s r = 0.48), suggesting
two associated but distinct constructs. The factor loadings on spasms (0.31 for factor 1) and on
constipation (0.28 for factor 2) were weak.
Internal Consistency and Test-Retest Reliability
The Cronbach’s alpha for the combined sample was 0.66; it was higher in MS (0.70) than in
patients with IPD, MSA or PSP (0.60). Given that the IPOS Neuro-S8 had only eight items
with two moderately correlated factors, we interpreted the internal consistency of the scale as
acceptable. The test-retest analysis revealed the agreement between the baseline and the week 6
assessments was fair, with an ICC value of 0.58 (95%CI: 0.28–0.83). The baseline total scores
were not significantly different from those of week 6 (p for paired t-test = 0.80).
Construct Validity
The IPOSNeuro-S8 was moderately correlated with the core POS (Pearson r 0.50, 95%CI: 0.36–
0.62) (Table 4). The correlation between IPOSNeuro-S8 and core POS were similar (r = 0.58) in
the two diagnostic groups. The correlation with existing disease specificmeasures (MSIS-Physi-
cal/ Psychological, PDQ, NMSQuest) was alsomoderate, ranging from 0.46 to 0.59 but statisti-
cally significant (p<0.05). The IPOSNeuro-S8 was negatively correlated with both EQ-5D and
health status (-0.39 and -0.25), and positively correlated with the HADS-14 (0.29).
The mean scores were different according to the EDSS score in MS sample (4.8 for EDSS
<8 versus 6.9 for EDSS 8+), the difference did not reach the significance level (p = 0.08). In the
IPD, MSA & PSP group, the H&Y staging system distinguished patients well, with higher
scores corresponding to more severe symptoms (7.2 H&Y stage 3 vs 9.7 H&Y stage 4 & 5), and
the difference was statistically significant (p = 0.020).
The two factors identified in the CFA were both strongly correlated with the total score
(Pearson’s r = 0.91 for Factor 1 and 0.71 for Factor 2); but were only weakly related to each
Psychometric Properties of an Outcome Measure for Long Term Neurological Conditions
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other (Pearson’s r = 0.35). The association pattern was similar in both conditions, providing
further proof that the two factors reflect a different but related symptom profile.
Responsiveness, MID and Longitudinal Construct Validity
The IPOS Neuro-S8 was responsive to change. This was more evident for patients with MS
when comparing the patients in the intervention arm to those in the control arm. The t-test
result was statistically significant (p = 0.030, t = 2.23, df = 46). The score change in IPD and the
combinedMSA & PSP was in the same direction (mean change -0.45 and -0.88), but none of
the changes reached significance level and the changes between groups were also not significant
(p = 0.54, t = 0.62, df = 70). The effect size (ES) of the short-term palliative care intervention in
MS patients was small (<0.5). The MID was 3.1 as measured by SEM, greater than half and a
third of SD (1.7 and 1.1).
Longitudinally, the IPOS Neuro-S8 showed reasonable correlation with the core POS and
with the disease specificmeasures. However, few of them reached statistical significance due to
the sample size reduction caused by attrition.
Discussion
This study provided initial evidence on the cross sectional and longitudinal reliability and
validity of the IPOS Neuro-S8, a new PCOM for people with progressive LTNCs. The IPOS
Neuro-S8 showed acceptable to promising psychometric properties for use across neurological
conditions, including advancedMS, late stage progressive IPD, PSP and MSA.While most
studies involving severely ill people often suffer from small numbers [41, 42], this evaluation
was based on a relatively large sample (N = 134) therefore making it statistically more robust.
The reliability of the IPOS Neuro-S8 appears adequate based on a Cronbach’s alpha value of
0.66 with only 8 items, and supported by the two factor solution and their moderate correlation
(Pearson’s r = 0.48) [43, 44]. The IPOS Neuro-S8 is correlated reasonably well with the non-
condition specific core POS. The core POS, as a multidimensional measure, only two out of its
ten items are questions about pain and one other physical symptom. Therefore, a high correla-
tion between IPOS Neuro-S8 and core POS is not anticipated.
The correlation between IPOSNeuro-S8 and the diagnosis specific scales (MSIS-29,
NMSQuest-30 and PDQ-8) was as expected (Pearson’s r range: 0.46–0.59), e.g. higher in physical
Table 3. Standardized Factor Loadings (Standard Error, SE), factor correlation (SE) and the fit indi-
ces in the confirmatory factor analysis of the IPOS Neuro-S8.
Item Factor1(5 items) Factor2(3 items)
Pain 0.61(0.09)
Shortness of breath 0.43(0.10)
Nausea 0.99(0.10)
Vomiting 0.64(0.08)
Constipation 0.28(0.09)
Spasms 0.31(0.10)
Difficulty in sleep 0.49(0.09)
Mouth problems 0.49(0.09)
Correlation of the two factors 0.48(0.11)
Fit statistics P = 0.19(Chi-square = 24.2, DF = 19)
Standardised RMR(SRMR) = 0.057
RMSEA = 0.046
Comparative fit index = 0.9634
doi:10.1371/journal.pone.0165379.t003
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Table 4. Cross-sectional and longitudinal reliability and validity of the IPOS Neuro-S8.
Psychometric properties Measure Time
scale
All (N = 134) MS (N = 52) IPD,MSA &PSP (N = 82)
Cross-sectional
Internal consistency (Cronbach alpha) Full scale T0 0.66 0.70 0.60
Construct validity
Concurrent (Pearson’s r, 95%CI) Core POS T0 0.50(0.36 to
0.62)
0.58(0.36 to 0.74) 0.58(0.41 to 0.71)
MSIS physical T0 - 0.59(0.36 to 0.75) -
MSIS
psychological
T0 - 0.46(0.20 to 0.66) -
NMSQuest T0 - - 0.58(0.43 to 0.71)
PDQ-8 T0 - - 0.48(0.29 to 0.63)
Discriminative or known group (Mean
(SD))
EDSS (<8 vs 8+) T0 - 4.8(2.1) vs 6.9(5.6)1 -
H&Y 3 vs 4&5 T0 - 7.2(4.1) vs 9.7(4.5)2
Convergent (Pearson’s r, 95%CI) Factor 1 vs total
score
T0 0.92(0.88 to
0.94)
0.91(0.85 to 0.95) 0.91(0.86 to 0.94)
Factor 2 vs total
score
T0 0.71(0.62 to
0.79)
0.73(0.57 to 0.84) 0.71(0.58 to 0.80)
Factor 1 vs Factor
2 score
T0 0.37(0.22 to
0.51)
0.40(0.14 to 0.61) 0.35(0.14 to 0.52)
Longitudinal
Test-retest reliability ICC (95%CI) T0 vs
wk6
- 0.62(0.36 to 0.82) -
Construct validity
Concurrent (Pearson’s r, 95%CI) Core POS T0 to
wk12
0.30(0.12 to
0.45)
0.16(-0.13 to 0.42) 0.56(0.38 to 0.70)
MSIS physical T0 to
wk12
- 0.41(0.12 to 0.63) -
MSIS
psychological
T0 to
wk12
- 0.05(-0.25 to 0.33) -
NMSQuest T0 to
wk12
- - 0.18(-0.06 to 0.39)
PDQ-8 T0 to
wk12
- - 0.27(0.03 to 0.47)
Responsiveness(change score) Mean (SD, 95%CI) T0 to
wk12
-0.42(3.4, -1.02
to 0.19)
-0.15(4.1, -1.33 to 1.04) -0.60(2.8, -1.26 to 0.06)
To intervention: Intervention vs
standard care
- -1.31(4.3, -3.04 to 0.43) vs
1.23(3.4, -0.28 to 2.74)3
-
To disease trajectory by type of
diagnosis (IPD vs MSA & PSP)
- -0.45(2.9, -1.29 to 0.40) vs
-0.88(2.7, -1.99 to 0.23)4
Minimally important difference(MID)*:
distribution based approach
SEM T0 to
wk12
3.1 2.9 2.9
1/2 SD T0 to
wk12
1.7 2.1 1.4
1/3 SD T0 to
wk12
1.1 1.4 0.9
1: p for two sample t-test = 0.08
2: p for two sample t-test = 0.020
*Standard error of measurement (SEM) = SDbaseline × sqrt (1-ICC). The MID measures for MS group was based on the patients in the intervention group
only.
3: mean (sd, 95%CI) for intervention and standard care group, respectively. The difference was significant (p = 0.030).
4: mean (sd, 95%CI) for IPD and the MSA&PSP combined, respectively. The difference was not statistically significant (p = 0.54).
doi:10.1371/journal.pone.0165379.t004
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and lower in psychological aspects. One reason for the moderate associationmay be that none of
thesemeasures were designed specifically for palliative care needs or for people severely affected
by their illness; thus, intrinsically thesemeasures may not capture the same needs as those cap-
tured by the IPOSNeuro-S8 [5, 7, 8, 23]. The time frames used in the disease specificmeasures
may be another reason. For example, NMQuest-30 and PDQ-8 ask symptoms experiencedover
the past month (or 4 weeks) and the MSIS is based on the past two weeks. In contrast, the IPOS
Neuro-S8 asks about the past three days, aiming to capture the immediate care needs. For
patients with neurological conditions who require palliative care input, the disease trajectory is
more unpredictable and more frequent assessments are recommended as best practice [9].
Our results support the continued development and validation of the IPOSNeuro-S8. If
proved by further validation studies, it can be a useful outcomemeasure in research settings, par-
ticularly for patients with progressive LTNCs, as it is brief and shows promising psychometric
properties. It may also facilitate the clinical use of the IPOSNeuro-S8 as a screeningmeasure in
non-palliative care settings, to increase the opportunities of identifying patients with palliative
care needs and trigger the referral process. In palliative care clinical practice, it may be used to
monitor care intervention outcomes and disease progression. At the organisation level, it can be
a simple, standardised auditing tool. It also makes patient’s self-monitoring possible.
Several limitations are noted in our study. We could not test face validity and content valid-
ity in this study, but all eight items of the IPOS Neuro-S8 were important for patients and rele-
vant in clinical practices [9, 18]. Although having been able to assess a range of psychometric
properties, this evaluation was based on two existing datasets using very different study
designs–a longitudinal observational study and a randomised clinical trial. Previous research
revealed that eligibility criteria for patient selection in clinical trials can be very restrictive,
therefore these patient samples may not be as representative as those from observational stud-
ies [45]. Some very “severe” patients were excluded as well–less than 5% got the highest possi-
ble score on the individual items; we did not have data for other prevalent neurological
conditions that may have a higher need for palliative care, e.g. motor neuron diseases. As a con-
sequence of the high attrition rate and the loss of statistical power, the longitudinal psychomet-
ric evaluation should be treated as preliminary. Furthermore, the psychometric testing in this
study was primarily based on classical test theory; it may be of interest to compare how the
results differ from those derived frommodernmeasurement theories.
Conclusions
In conclusion, our results demonstrated the acceptable to promising psychometric properties of
the IPOSNeuro-S8 in two common long term neurological conditions. The IPOSNeuro-S8
showed good data quality, borderline floor effects and no ceiling effects, good internal consistency
and moderate test-retest reliability. A moderately correlated two-factor structure was confirmed.
The IPOSNeuro-S8 was moderately correlated with both the generic core POS and the condition
specificmeasures (MSIS-29, NMSQuest-30, PDQ-8). There was evidence for discriminant validity
in IPD, MSA and PSP (by disease progression). Preliminary evidence suggested good responsive-
ness and longitudinal construct validity but needs further research. Future work needs to confirm
these findings with larger samples and its usefulness in wider LTNC disease groups.
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